跳至主要内容
临床试验/NCT00997061
NCT00997061已完成不适用

SCOT Registry: Small Cell Lung Cancer Treatment and Outcome

GlaxoSmithKline1 个研究点 分布在 1 个国家目标入组 500 人开始时间: 2009年11月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
500
试验地点
1
主要终点
Registry with disease, treatment and outcome data collected.

研究概览

简要总结

The registry is an international, multicenter, observational registry of newly diagnosed patients with SCLC.

Data will be entered into an electronic CRF (eCRF) via Internet access. Treatment plan remains the responsibility of the patient's physician and data collected in this registry will reflect a "real world" approach of the diagnosis and treatment of patients with SCLC.

Approximately 60 centres in 13 countries will take part in this registry. It is expected that about 500 patients will be recruited during a period of 6 to 9 months according to the feasibility.

研究设计

研究类型
Observational
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Male or Female >/= 18 years
  • Diagnosis of small cell lung cancer
  • Patient newly diagnosed with SCLC
  • Has given written informed consent (if applicable)

排除标准

  • Concurrent history of other neoplasm, except curatively treated basal cell skin cancer or adequately treated in-situ carcinoma of the cervix.
  • Patient presenting with recurrence of SCLC.
  • Patients who has received any chemotherapy for the SCLC.

研究组 & 干预措施

HYCAMTIN

干预措施: HYCAMTIN (Drug)

结局指标

主要结局

Registry with disease, treatment and outcome data collected.

时间窗: 6-9mth recruitment period, 18mth study duration.

次要结局

  • survival rates(18 month period)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验